Gilead Sciences, Inc. (NASDAQ:GILD) EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction on Friday, December 1st. The stock was sold at an average price of $74.64, for a total transaction of $1,119,600.00. Following the completion of the transaction, the executive vice president now directly owns 70,988 shares in the company, valued at $5,298,544.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Gilead Sciences, Inc. (NASDAQ GILD) opened at $73.29 on Thursday. The firm has a market cap of $95,736.46, a PE ratio of 7.65, a price-to-earnings-growth ratio of -1.23 and a beta of 1.13. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $86.27. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. The business had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company’s revenue was down 13.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.75 earnings per share. sell-side analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be given a $0.52 dividend. The ex-dividend date is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.84%. Gilead Sciences’s dividend payout ratio (DPR) is currently 23.69%.

GILD has been the topic of several analyst reports. BMO Capital Markets reaffirmed a “hold” rating and issued a $82.00 price target on shares of Gilead Sciences in a report on Friday, October 20th. J P Morgan Chase & Co set a $85.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Monday, August 28th. Vetr raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 price target on the stock in a report on Wednesday, September 6th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $83.00 price target (up from $77.00) on shares of Gilead Sciences in a report on Friday, October 6th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $85.22.

Institutional investors have recently modified their holdings of the business. BlackRock Inc. increased its stake in shares of Gilead Sciences by 1.9% during the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after purchasing an additional 1,937,031 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Gilead Sciences by 1.0% during the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after purchasing an additional 310,607 shares in the last quarter. FMR LLC increased its stake in shares of Gilead Sciences by 1.1% during the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after purchasing an additional 258,005 shares in the last quarter. Finally, Northern Trust Corp increased its stake in shares of Gilead Sciences by 0.7% during the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after purchasing an additional 116,780 shares in the last quarter. Institutional investors and hedge funds own 76.23% of the company’s stock.

WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/12/07/gregg-h-alton-sells-15000-shares-of-gilead-sciences-inc-gild-stock-2.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.